The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

Abstract Insulin resistance and hepatic lipid accumulation constitute the metabolic underpinning of nonalcoholic steatohepatitis (NASH). We tested the hypothesis that saroglitazar, a PPAR α/γ agonist would improve NASH in the diet-induced animal model of NAFLD. Mice received chow diet and normal wat...

Full description

Bibliographic Details
Main Authors: Divya P. Kumar, Rebecca Caffrey, Jonathon Marioneaux, Prasanna K. Santhekadur, Madhavi Bhat, Cristina Alonso, Srinivas V. Koduru, Binu Philip, Mukul R. Jain, Suresh R. Giri, Pierre Bedossa, Arun J. Sanyal
Format: Article
Language:English
Published: Nature Publishing Group 2020-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-020-66458-z

Internet

https://doi.org/10.1038/s41598-020-66458-z

Similar Items